More than 600 people in England with a form of lung cancer could benefit from the innovative drug osimertinib (Tagrisso) after its approval by the National Institute for Health and Care Excellence (NICE).

The drug will now be available to people with early-stage non small cell lung cancer (NSCLC) who have had surgery to remove their tumour that has errors in a gene called EGFR.

An immunotherapy combination could be better than standard ‘Extreme’ chemotherapy as first-line treatment for some patients with relapsed or metastatic head and neck cancer, or both, a major phase III trial suggests.

Cancer services at University Hospitals Coventry and Warwickshire (UHCW) NHS Trust are set for a ground-breaking advancement, with major funding secured to develop technology that can detect tumours and guide robots to remove them.

The Terabotics project, which is being led by Professor Emma Pickwell-MacPherson at the University of Warwick, will use probes that use terahertz (THz) radiation, or T-rays, to scan for tumours under the skin.